Hollis-Eden touts new diabetes data; Nastech announces positive insulin report

> Hollis-Eden says new data from a Phase I/II trial of triolex for type 2 diabetes continues to show the drug is safe and well tolerated while also demonstrating that it significantly improves insulin sensitivity and improved other key targets. Report

> Nastech Pharmaceutical announced positive Phase II data demonstrating that its intranasal insulin was both superior to usual therapy and non-inferior to insulin aspart, a rapid-acting injectable insulin, in maintaining glucose control at both 60 and 90 minutes following a meal. Release

> The UK's Bioniq has won a 50,000 euro investment to advance its work on an anti-malaria drug. Report

> It's been rumored for weeks, and now Sanofi-Aventis is confirming. Yes, the French drugmaker will cut jobs at home in France. Details are sketchy, but here's what we know: Sanofi will lay off 700 to 800 sales reps. Layoff report

> Think the FDA has been falling all over itself to issue warning letters lately? Think again. A look at agency statistics showed that the number of warning letters actually dropped by half--yes, half--in the last 10 years. FDA report

> There's been a lot of talk lately about whether a "by the numbers" approach to disease is really effective. Report

> Curious about the man Jeff Kindler brought in to strategize about Pfizer's finances? The Star-Ledger pulls back the curtain on CFO Frank D'Amelio (photo), the ex-Lucent exec who's charged with executing an equally dramatic makeover at Pfizer. Report

And Finally... Duke engineers say that a genetic tool used by medical researchers may also be used in a novel approach to remove harmful microbes and viruses from drinking water. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.